Impact of vitamin d dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet

Martin Wilkie, Giuseppe Pontoriero, Fernando MacÁrio, Magdi Yaqoob, Koen Bouman, Johann Braun, Beat Von Albertini, Hans Brink, Francisco Maduell, Helmut Graf, João M. Frazão, Willem Jan Bos, Vicente Torregrosa, Heikki Saha, Helmut Reichel, Valter J. Zani, Dave Carter, Piergiorgio Messa

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aims: The calcimimetic cinacalcet (Mimpara®/Sensipar®) simultaneously lowers parathyroid hormone (PTH), phosphorus (P) and calcium (Ca) levels in patients with secondary hyperparathyroidism. The OPTIMA study demonstrated that cinacalcet and adjusted doses of vitamin D maximized control of these parameters. This post-hoc analysis of OPTIMA data assessed the impact of reducing or increasing the dose of concomitant vitamin D on PTH, P and Ca in patients receiving cinacalcet. Methods: Dialysis patients with mean baseline intact PTH (iPTH) 300-800 pg/ml (31.8-84.8 pM) received doses of cinacalcet titrated to achieve an iPTH of 150-300 pg/ml (15.9-31.8 pM). The dose of vitamin D could then be decreased to further reduce serum P or Ca, or increased/initiated to further decrease PTH levels if iPTH >300 pg/ml or to increase Ca if Ca

Original languageEnglish
JournalNephron - Clinical Practice
Volume112
Issue number1
DOIs
Publication statusPublished - May 2009

Keywords

  • Calcimimetic
  • Calcium
  • Calcium-phosphorus product
  • Cinacalcet
  • Parathyroid hormone
  • Phosphorus
  • Secondary hyperparathyroidism
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Impact of vitamin d dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet'. Together they form a unique fingerprint.

Cite this